Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Q3 2022 Earnings Presentation
20 slides from Bico Group Ab Class B's earnings presentation, Nov 9, 2022
Slide 1: Q3 Presentation / Earnings Call
Q3 PR ES E N TAT I O N / 9 N OV E M B E R 2 02 2 / E A R N I N GS C A L L
Slide 2: Presenters: Erik Gatenholm and Mikael Engblom
ERIK GATENHOLM / PRESIDENT AND CEO MIKAEL ENGBLOM / INTERIM GROUP CFO 2 Q3 2 P R E S E N TAT I O N 2 0 2 2
Slide 3: Bioprinting, Biosciences, Bioautomation
BIOPRINTING BIOSCIENCES BIOAUTOMATION 3 Q3 2 P R E S E N TAT I O N 2 0 2 2
Slide 4: The BICO Journey
The BICO Journey BICO’s mission is to enable the pharmaceutical and biopharma industries We are now well positioned for growth, establishing us as a leading to develop new drugs faster and safer, with more specificity and less provider of drug discovery and development tools. The result is an need f
Slide 5: Agenda
AGENDA This is BICO “BICO’s mission is to enable the pharmaceutical Q3 Highlights and biopharma industries to develop new treatments, faster and safer, with more Financial Performance specificity and less need for animal testing.” ERIK GATENHOLM / PRESIDENT AND CEO Performace Update per Business Are
Slide 6: Q3 Highlights
Q3 Highlights 6 Q 3 P R E S E N TAT I O N 2 0 2 2
Slide 7: Q3 in summary
Q3 in summary 1 STRONG PRODUCT DEMAND AND HIGH SALES 2 FOCUS ON IMPROVING PROFITABILITY AND CASH FLOW 3 FOCUS ON OPERATIONAL EFFICIENCY AND ACQUISITION SYNERGIES 4 COST-REDUCTION PROGRAM LAUNCHED 7 Q 3 P R E S E N TAT I O N 2 0 2 2
Slide 8: Financial Performance / Q3
Financial Performance / Q3 8 Q 3 P R E S E N TAT I O N 2 0 2 2
Slide 9: Q3 July–September 2022 net sales
Q3 JULY – SEPTEMBER 2022 NET SALES 74 66.5 MSEK / ROLLING 12 MONTHS TOTAL SALES GROWTH NET PROFIT/LOSS 2000 20 /% / MSEK 1800 1600 15 1400 1200 1.8 76.5 1000 10 EBITDA GROSS MARGIN 800 / MSEK /% 600 5 400 18.1 550.6 200 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2020 2021 2022 ADJUSTE
Slide 10: January–September 2022 net sales
Q3 JANUARY – SEPTEMBER 2022 112 66.1 NET SALES MSEK / ROLLING 12 MONTHS TOTAL SALES GROWTH NET PROFIT/LOSS 2000 20 /% / MSEK 1800 1600 15 1400 -80.6 74.5 1200 1000 10 EBITDA GROSS MARGIN 800 / MSEK /% 600 5 400 35.3 1,565.4 200 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2020 2021 2022
Slide 11: Focus on strengthening cash flow
Focus on strengthening JULY – SEPTEMBER 2022 JANUARY – SEPTEMBER 2022 cash flow CASH FLOW FROM OPERATING ACTIVITIES Cash flow including changes in short-term investments during the third quarter amounted to SEK -303 million, reducing total cash reserves from SEK 991 million per June 30 to SEK 688 mi
Slide 12: Performance per Business Area
Performance per Business Area 12 Q 3 P R E S E N TAT I O N 2 0 2 2
Slide 13: Bioprinting
Bioprinting JULY – SEPTEMBER 2022 JANUARY – SEPTEMBER 2022 33 39 ORGANIC GROWTH ORGANIC GROWTH /% /% 145.7 422.4 NET SALES NET SALES / MSEK / MSEK BioNovaX, launched by Allegro, which only joined the BICO family in May 2022. The bioNovaX accelerates research in 1.3 10.2 biomimetic models, regenerati
Slide 14: Biosciences
Biosero continues to develop well, announcing a key patent underlying its Green Button Go® laboratory automation scheduling software. Biosciences This year Biosero also installed what may be the largest automated cancer diagnosis system in the world. JULY – SEPTEMBER 2022 JANUARY – SEPTEMBER 2022 Th
Slide 15: Bioautomation
Bioautomation Providing relevant innovations under well-established brands to our target customers in diagnostics and pharma is a key driver for profitable growth. JULY – SEPTEMBER 2022 JANUARY – SEPTEMBER 2022 One great example of this is how we strengthen our single-cell proteomics offerings throu
Slide 16: Outlook
Outlook 16 Q 3 P R E S E N TAT I O N 2 0 2 2
Slide 17: Outlook
Outlook 1 The medium and long-term prospects are encouraging. 2 Great continued potential and growth opportunities in the majority of companies in the group. 3 The main driver is big pharma’s vigorous move towards laboratory automation. 4 Our strong technology platform keeps competitors at bay, and
Slide 18: Upcoming Events
Upcoming Events NOVEMBER 10, 2022 Digital Capital Markets Day FEBRUARY 23, 2023 Year-end report 2022 January–December 2022 MARCH 15, 2023 Bioconvergence is Annual report 2022 enabling the future of health MAY 4, 2023 Interim report Q1 2023 Bioconvergence is an emerging industry segment within health
Slide 19: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.
Slide 20: Join the Convergence Revolution
JOIN THE Bro CONVERGENCE REVOLUTION >>